Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ALNY
  • CUSIP: 02043Q10
Key Metrics:
  • Previous Close: $46.62
  • 50 Day Moving Average: $42.20
  • 200 Day Moving Average: $50.61
  • 52-Week Range: $31.38 - $80.11
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.82
  • P/E Growth: -0.20
  • Market Cap: $4.37B
  • Outstanding Shares: 86,013,000
  • Beta: 2.69
Profitability:
  • Net Margins: -869.63%
  • Return on Equity: -37.25%
  • Return on Assets: -30.67%
Debt:
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 9.14%
  • Quick Ratio: 9.14%
Additional Links:
Companies Related to Alnylam Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (?)
Ratings Breakdown: 7 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $65.44 (27.53% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Show:
DateFirmActionRatingPrice TargetDetails
2/9/2017Needham & Company LLCReiterated RatingBuy$98.00 -> $68.00View Rating Details
2/3/2017JMP SecuritiesSet Price TargetBuy$69.00View Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$75.00View Rating Details
1/9/2017Chardan CapitalBoost Price TargetBuy$69.00 -> $97.00View Rating Details
12/25/2016Credit Suisse GroupSet Price TargetBuy$50.00View Rating Details
12/1/2016Jefferies Group LLCSet Price TargetBuy$58.00View Rating Details
11/10/2016Leerink SwannReiterated RatingMarket Perform$43.00View Rating Details
11/3/2016FBR & CoReiterated RatingBuy$100.00View Rating Details
11/3/2016Cowen and CompanyReiterated RatingBuyView Rating Details
11/3/2016Barclays PLCReiterated RatingHold$50.00View Rating Details
10/24/2016Piper Jaffray CompaniesReiterated RatingOverweight$106.00View Rating Details
10/7/2016Morgan StanleyDowngradeOverweight -> Equal Weight$38.00 -> $36.00View Rating Details
10/6/2016Goldman Sachs Group, Inc. (The)Lower Price TargetNeutral$65.00 -> $34.00View Rating Details
10/6/2016Stifel NicolausLower Price TargetHold$68.00 -> $36.00View Rating Details
10/6/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$83.00 -> $51.00View Rating Details
9/28/2016Janney Montgomery ScottInitiated CoverageNeutral$74.00View Rating Details
11/26/2015S&P Equity ResearchDowngradeBuy -> HoldView Rating Details
6/24/2015Deutsche Bank AGSet Price TargetBuy$155.00View Rating Details
6/24/2015Canaccord GenuityReiterated RatingBuy$160.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017        
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.66)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.60)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.56)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($0.54)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Current Year EPS Consensus Estimate: $-5.09 EPS
Next Year EPS Consensus Estimate: $-4.74 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.14)($1.08)($1.11)
Q2 20164($1.32)($1.19)($1.26)
Q3 20164($1.35)($1.25)($1.30)
Q4 20163($1.45)($1.27)($1.38)
Q1 20172($1.36)($1.30)($1.33)
Q2 20172($1.36)($1.30)($1.33)
Q3 20172($1.36)($1.21)($1.29)
Q4 20172($1.37)($1.19)($1.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 88.70%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.35View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.00View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.00View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.60View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.00View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)
DateHeadline
News IconTechnical Indicator Review on Shares of Alnylam Pharmaceuticals Inc (ALNY) - Midway Monitor (NASDAQ:ALNY)
midwaymonitor.com - February 27 at 3:36 PM
News IconStock Review for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Providence Standard (NASDAQ:ALNY)
providencestandard.com - February 24 at 8:40 PM
News IconStock Review for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ... - Providence Standard (NASDAQ:ALNY)
providencestandard.com - February 24 at 8:40 PM
News IconMarket Review: Focusing on These Shares: Alnylam Pharmaceuticals Inc (ALNY) - BVN (NASDAQ:ALNY)
bvnewsjournal.com - February 24 at 3:39 PM
News IconAre Analysts Optimistic About Where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is Heading? - Winfield Review (NASDAQ:ALNY)
winfieldreview.com - February 24 at 3:39 PM
News IconMarket Spotlight: Focusing on Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Rives Journal (NASDAQ:ALNY)
rivesjournal.com - February 23 at 8:32 PM
News IconCompany in Focus: Alnylam Pharmaceuticals Inc (ALNY) - Baldwin Journal (NASDAQ:ALNY)
baldwinjournal.com - February 23 at 3:29 PM
nasdaq.com logoCommit To Purchase Alnylam Pharmaceuticals At $35, Earn 20.9 ... - Nasdaq (NASDAQ:ALNY)
www.nasdaq.com - February 23 at 3:29 PM
News IconNumbers in Focus for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - The Standard (NASDAQ:ALNY)
6milestandard.com - February 22 at 3:29 PM
News IconNews Impact Score Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) At 69 - Stock Observer (NASDAQ:ALNY)
www.thestockobserver.com - February 22 at 3:29 PM
finance.yahoo.com logoALNYLAM PHARMACEUTICALS, INC. Financials (NASDAQ:ALNY)
finance.yahoo.com - February 22 at 3:29 PM
News IconChecking the Levels for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Searcy News (NASDAQ:ALNY)
searcysentinel.com - February 21 at 3:44 PM
fool.com logoBetter Buy: Alnylam Pharmaceuticals, Inc. vs. BioMarin Pharmaceutical Inc. - Motley Fool (NASDAQ:ALNY)
www.fool.com - February 21 at 7:04 AM
News IconAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Honing in on ... - Rockville Register (NASDAQ:ALNY)
rockvilleregister.com - February 17 at 6:38 PM
News IconAlnylam Pharmaceuticals, Inc. (ALNY): Essential Chart Information - NY Stock News (NASDAQ:ALNY)
nystocknews.com - February 17 at 6:38 PM
News IconThe pharma industry is worried about Trump's push for radical shift at the FDA (NASDAQ:ALNY)
www.businessinsider.com - February 16 at 8:33 PM
4-traders.com logoAlnylam Pharmaceuticals : Presents New Data on Fitusiran at EAHAD (NASDAQ:ALNY)
www.4-traders.com - February 16 at 8:33 PM
News IconInside the Numbers on Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - The Standard (NASDAQ:ALNY)
6milestandard.com - February 16 at 3:31 PM
News IconEPS Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) At $-1.22 - Stock Observer (NASDAQ:ALNY)
www.thestockobserver.com - February 16 at 3:31 PM
News IconIs The Sell-Side Predicting That Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Will Move Higher? - Winfield Review (NASDAQ:ALNY)
winfieldreview.com - February 16 at 8:08 AM
News IconNews Impact Score Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) At 84 - Stock Observer (NASDAQ:ALNY)
www.thestockobserver.com - February 16 at 8:08 AM
biz.yahoo.com logoALNYLAM PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report (NASDAQ:ALNY)
biz.yahoo.com - February 16 at 8:08 AM
4-traders.com logoPharma industry shuns Trump push for radical shift at FDA (NASDAQ:ALNY)
www.4-traders.com - February 15 at 2:05 AM
News IconTechnical Update on Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Baldwin Journal (NASDAQ:ALNY)
baldwinjournal.com - February 14 at 4:02 PM
realistinvestor.com logoAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EPS Projection At $-1.05 - RealistInvestor.com (NASDAQ:ALNY)
www.realistinvestor.com - February 14 at 4:02 PM
capitalcube.com logoETFs with exposure to Alnylam Pharmaceuticals, Inc. : February 14, 2017 (NASDAQ:ALNY)
www.capitalcube.com - February 14 at 4:02 PM
capitalcube.com logoAlnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017 (NASDAQ:ALNY)
www.capitalcube.com - February 13 at 3:56 PM
News IconMarket for Huntingtons Disease Therapeutics Will Continue to Grow by 2021 (NASDAQ:ALNY)
www.medgadget.com - February 13 at 1:31 AM
News IconAlnylam Pharmaceuticals, Inc. (ALNY) Forecasted to Earn FY2021 Earnings of ($0.81) Per Share (NASDAQ:ALNY)
www.topix.com - February 12 at 8:29 PM
finance.yahoo.com logoAlnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance (NASDAQ:ALNY)
finance.yahoo.com - February 12 at 3:28 PM
News IconNeedham Just Issued "Buy" Rating on Alnylam Pharmaceuticals (ALNY) (NASDAQ:ALNY)
prensariotiretail.com - February 12 at 1:29 AM
News IconLooking at the Tea Leaves for Alnylam Pharmaceuticals, Inc. (ALNY) - The USA Commerce (NASDAQ:ALNY)
theusacommerce.com - February 11 at 1:59 AM
businesswire.com logoAlnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Business Wire (press release) (NASDAQ:ALNY)
www.businesswire.com - February 11 at 1:59 AM
seekingalpha.com logoAlnylam Pharmaceuticals, Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:ALNY)
seekingalpha.com - February 10 at 8:57 PM
capitalcube.com logoAlnylam Pharmaceuticals, Inc. :ALNY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017 (NASDAQ:ALNY)
us.rd.yahoo.com - February 10 at 8:57 PM
us.rd.yahoo.com logoAlnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:ALNY)
us.rd.yahoo.com - February 10 at 8:57 PM
News IconChartists Perspective on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Rives Journal (NASDAQ:ALNY)
rivesjournal.com - February 10 at 3:57 PM
fool.com logoAlnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It - Motley Fool (NASDAQ:ALNY)
www.fool.com - February 10 at 3:56 PM
News IconWhat The Charts Are Saying About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Piedmont Register (NASDAQ:ALNY)
piedmontregister.com - February 9 at 8:32 PM
News IconAlnylam Pharmaceuticals, Inc. Presents Progress -- Investors Dig It - Madison.com (NASDAQ:ALNY)
host.madison.com - February 9 at 8:32 PM
finance.yahoo.com logoAlnylam's Healthy Earnings Boost Price, Prompts Vetr Users To Call Hold (NASDAQ:ALNY)
finance.yahoo.com - February 9 at 8:32 PM
seekingalpha.com logoAlnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:ALNY)
seekingalpha.com - February 9 at 3:30 PM
businesswire.com logoAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period ... - Business Wire (press release) (NASDAQ:ALNY)
www.businesswire.com - February 9 at 3:30 PM
finance.yahoo.com logoEdited Transcript of ALNY earnings conference call or presentation 8-Feb-17 9:30pm GMT (NASDAQ:ALNY)
finance.yahoo.com - February 9 at 3:30 PM
finance.yahoo.com logoAlnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise (NASDAQ:ALNY)
finance.yahoo.com - February 9 at 3:30 PM
bizjournals.com logo​Alnylam shares jump on positive earnings, 2017 outlook (NASDAQ:ALNY)
www.bizjournals.com - February 9 at 3:30 PM
rttnews.com logoEARNINGS SUMMARY: Details of Alnylam Pharmaceuticals Inc. Q4 Earnings Report (NASDAQ:ALNY)
www.rttnews.com - February 9 at 1:44 AM
us.rd.yahoo.com logoAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity (NASDAQ:ALNY)
us.rd.yahoo.com - February 9 at 1:43 AM
reuters.com logoBRIEF-Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent ... - Reuters (NASDAQ:ALNY)
www.reuters.com - February 8 at 8:42 PM
sg.finance.yahoo.com logoAlnylam reports 4Q loss (NASDAQ:ALNY)
sg.finance.yahoo.com - February 8 at 8:42 PM

Social

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Where is Alnylam Pharmaceuticals' stock going? Where will Alnylam Pharmaceuticals' stock price be in 2017?

16 brokers have issued 12 month price objectives for Alnylam Pharmaceuticals' shares. Their predictions range from $34.00 to $106.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $65.44 in the next year.

When will Alnylam Pharmaceuticals announce their earnings?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What are analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:

  • Chardan Capital analysts commented, "We now seen Alnylam as the leader in the clinical HBV RNAi therapy space. As discussed in our 14 October 2016 company note for Arbutus (Buy), we believe ARB-1467 has demonstrated at best mediocre phase IIa results that were predictable based on inferior preclinical data relative to Alnylam’s RNAi asset, ALN-HBV . Additionally, ALN-HBV has a favorable dosing route in subcutaneous delivery compared to Arbutus’ ARB-1467 and ARB-1740, which are administered by intravenous injection. With Arrowhead moving to preclinical development in HBV , we now view Alnylam as the leader in the space." (11/30/2016)

  • According to Zacks Investment Research, "Alnylam is a development-stage biopharmaceutical company focused on the development of RNAi-based therapeutics. The company expects to achieve the profile of three marketed products by the end of 2020. Investor focus should be on the company's progress with its late-stage pipeline candidate, patisiran. Meanwhile, Alnylam’s RNAi technology has allowed the company to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals will not only provide it with funds but also take its RNAi technology outside the core focus area. Estimate movement has been mixed lately ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters. However, the discontinuation of the phase III ENDEAVOUR study on revusiran, following the Data Monitoring Committee’s recommendation (DMC) is disappointing." (10/25/2016)

  • Needham & Company LLC analysts commented, "Alnylam announced additional data from its ongoing fitusiran Phase 1/2 trial in Hemophilia. Emerging safety and efficacy profile is consistent w/ prior clinical data and point to a differentiated once-monthly agent. Phase 3 initiation, however, has been pushed into 2017 (was 2H16). Regulators are seeking additional information around dose. Mgmt expects to complete dose-escalation in Hemophilia pts w/ Inhibitors later this yr." (7/25/2016)

Who owns Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Baillie Gifford & Co. (3.86%), State Street Corp (2.75%), RTW Investments LP (0.92%), 12 West Capital Management LP (0.81%) and Arrowpoint Asset Management LLC (0.81%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, David E I Pyott, David-Alexandre C Gros, Dennis A Ausiello, John Maraganore, Kevin P Starr, Michael W Bonney, Paul Schimmel, Philip A Sharp and Sanofi.

Who sold Alnylam Pharmaceuticals stock? Who is selling Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., RTW Investments LP, Allianz Asset Management AG, Baillie Gifford & Co., Oxford Asset Management, Credit Agricole S A, State Board of Administration of Florida Retirement System and Van ECK Associates Corp. Company insiders that have sold Alnylam Pharmaceuticals stock in the last year include Akshay Vaishnaw, John Maraganore and Philip A Sharp.

Who bought Alnylam Pharmaceuticals stock? Who is buying Alnylam Pharmaceuticals stock?

Alnylam Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including 12 West Capital Management LP, Arrowpoint Asset Management LLC, Boxer Capital LLC, Frontier Capital Management Co. LLC, ARK Investment Management LLC, Perceptive Advisors LLC, Russell Investments Group Ltd. and A.R.T. Advisors LLC. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, David-Alexandre C Gros, Michael W Bonney and Sanofi.

How do I buy Alnylam Pharmaceuticals stock?

Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alnylam Pharmaceuticals stock cost?

One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $51.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Earnings History Chart

Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Dividend History Chart

Dividend Payments by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Last Updated on 2/27/2017 by MarketBeat.com Staff